|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from (used in) operating activities [abstract] | |||||
| Profit before tax | |||||
| Adjustments for non-cash items: | |||||
| Depreciation, amortisation and impairment | |||||
| Net loss from investing activities | |||||
| Share of profit in associates and joint ventures | |||||
| Impairment of interest in associate | |||||
| (Gain)/loss on acquisition/disposal of subsidiaries, businesses, associates and joint ventures | |||||
| Change in expected credit losses gross of recoveries and other credit impairment charges | |||||
| Provisions including pensions | |||||
| Share-based payment expense | |||||
| Other non-cash items included in profit before tax | |||||
| Elimination of exchange differences | |||||
| Change in net trading securities and derivatives | |||||
| Change in loans and advances to banks and customers | |||||
| Change in reverse repurchase agreements – non-trading | |||||
| Change in financial assets designated and otherwise mandatorily measured at fair value | |||||
| Change in other assets | |||||
| Change in deposits by banks and customer accounts | |||||
| Change in repurchase agreements – non-trading | |||||
| Change in debt securities in issue | |||||
| Change in financial liabilities designated at fair value | |||||
| Change in other liabilities | |||||
| Dividends received from associates | |||||
| Contributions paid to defined benefit plans | |||||
| Tax paid | |||||
| Net cash from operating activities | |||||
| Cash flows from (used in) investing activities [abstract] | |||||
| Purchase of financial investments | |||||
| Proceeds from the sale and maturity of financial investments | |||||
| Net cash flows from the purchase and sale of property, plant and equipment | |||||
| Net cash flows from disposal of loan portfolio and customer accounts | |||||
| Net investment in intangible assets | |||||
| Net cash inflow on acquisition/disposal of subsidiaries, businesses, associates and joint ventures | |||||
| Net cash outflow on acquisition/disposal of subsidiaries, businesses, associates and joint ventures | |||||
| Net cash from investing activities | |||||
| Cash flows from (used in) financing activities [abstract] | |||||
| Issue of ordinary share capital and other equity instruments | |||||
| Share buy-backs | |||||
| Net purchases of own shares for market-making and investment purposes | |||||
| Net cash flow from change in stake of subsidiaries | |||||
| Redemption of preference shares and other equity instruments | |||||
| Subordinated loan capital issued | |||||
| Subordinated loan capital repaid | |||||
| Dividends paid to shareholders of the parent company and non-controlling interests | |||||
| Net cash from financing activities | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents at 1 Jan | |||||
| Exchange differences in respect of cash and cash equivalents | |||||
| Cash and cash equivalents at 31 Dec | |||||
| Cash and cash equivalents comprise: | |||||
| – cash and balances at central banks | |||||
| – items in the course of collection from other banks | |||||
| – loans and advances to banks of one month or less9 | |||||
| – reverse repurchase agreements with banks of one month or less | |||||
| – treasury bills, other bills and certificates of deposit less than three months | |||||
| – cash collateral, net settlement accounts and items in course of collection from/transmission to other banks | |||||
| – cash and cash equivalents held for sale | |||||
| – less: items in the course of transmission to other banks | |||||
Loading...
